Evidence map›Paper›PMID 32816079›Full record

ArticleAnnals of hematology2020

Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.

Silvia Chiesa, Stefan Hohaus, Lorenzo Falcinelli, Francesco D'Alò, Massimo Fabrizio Martelli, Stefania Manfrida, Francesco Beghella Bartoli, Cesare Colosimo, Vincenzo Valentini, Cynthia Aristei and 1 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Silvia ChiesaUOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.
Stefan HohausUOC di Ematologia, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Lorenzo FalcinelliSezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università degli studi di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy.
Francesco D'AlòUOC di Ematologia, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Massimo Fabrizio MartelliDivisione di Ematologia, Immunologia Clinica e Trapianto di midollo osseo, Dipartimento di Medicina, Università degli studi di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy.
Stefania ManfridaUOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.
Francesco Beghella BartoliUOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy. francesco.beghellabartoli@guest.policlinicogemelli.it.ORCID http://orcid.org/0000-0001-9017-0318
Cesare ColosimoIstituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Vincenzo ValentiniUOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.
Cynthia AristeiSezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università degli studi di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy.
Mario BalducciUOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to define the maximum tolerated dose (MTD) of temozolomide (TMZ) concurrent with radiotherapy (RT) after high-dose methotrexate (HD-MTX) for newly diagnosed primary central nervous system lymphoma (PCNSL). Adult patients with PCNSL were treated according to a response-adapted strategy. HD-MTX (3.5 g/m

Indexed as

ChemoradiotherapyCranial IrradiationAdolescentAdultAgedAntimetabolites, AntineoplasticAntineoplastic Agents, AlkylatingBrain NeoplasmsChemical and Drug Induced Liver InjuryChemotherapy, AdjuvantCognition DisordersConsolidation ChemotherapyFemaleHematologic DiseasesHumansKaplan-Meier EstimateAntimetabolites, AntineoplasticAntineoplastic Agents, AlkylatingMethotrexateTemozolomideChemoradiotherapyCNS lymphomaPhase I studyTemozolomide

Identifiers

PMID32816079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.